comparemela.com

Latest Breaking News On - Durect corporation - Page 9 : comparemela.com

DURECT Corporation s (DRRX) CEO Jim Brown on Q2 2022 Results - Earnings Call Transcript

DURECT Corporation (NASDAQ:NASDAQ:DRRX) Q2 2022 Earnings Conference Call August 4, 2022, 4:30 PM ET Company Participants Tim Papp - Chief Financial Officer Jim Brown - Chief Executive.

United statesEd arceKristen kluskaRick millerTim pappJim brownThomas yipFrancois briseboisNorman sussmanCompany participantsUs patent officeCantor fitzgeraldDurect corporationCorporation second quarterUnited states to innocoll pharmaceuticalsConference call august

DURECT Corporation Reports Second Quarter 2022 Financial Results and Update of Programs

/PRNewswire/ DURECT Corporation (Nasdaq: DRRX) today announced financial results for the three months ended June 30, 2022 and provided a corporate update..

United statesJamese brownDrug administrationInnocoll pharmaceuticalsInnocoll pharmaceuticals limitedExchange commissionInnocoll pharmaceuticals ltdUs patent officeCorporation nasdaqEarnings call todayRecent business highlightsPatent issuanceFast track designationNew drug applicationAlcohol associated hepatitisEnd stage liver disease

DURECT Corporation Appoints Timothy M Papp as Chief Financial Officer

/PRNewswire/ DURECT Corporation (Nasdaq: DRRX), a biopharmaceutical company focused on epigenetic regulation to develop treatments for acute organ injury.

United statesTimothym pappRodman renshawJamese brownDrug administrationInnocoll pharmaceuticalsExchange commissionWharton school of businessInnocoll pharmaceuticals ltdCorporation nasdaqDuke universityChief financialChief executive officerManaging directorHealthcare investmentHealthcare investment banking

DURECT Corporation to Present at the H C Wainwright Global Investment Conference

/PRNewswire/ DURECT Corporation (Nasdaq: DRRX) today announced that Dr. James E. Brown, President and CEO, Dr. Norman Sussman, Chief Medical Officer, and Dr..

United statesEd arceWeiqi linJamese brownNorman sussmanDrug administrationInnocoll pharmaceuticalsExchange commissionInnocoll pharmaceuticals ltdEquity researchCorporation nasdaqChief medical officerExecutive vice presidentManaging directorFast track designationDurect corporation

DURECT Corporation Reports First Quarter 2022 Financial Results and Update of Programs

/PRNewswire/ DURECT Corporation (Nasdaq: DRRX) today announced financial results for the three months ended March 31, 2022 and provided a corporate update..

United statesJamese brownExchange commissionInnocoll pharmaceuticals ltdDrug administrationCorporation nasdaqInnocoll pharmaceuticalsEarnings call todayRecent business highlightsEastern timeFast track designationAlcohol associated hepatitisLooking statementDurect corporation

vimarsana © 2020. All Rights Reserved.